Composition

• US 20100063175A1
• Filed: 02/01/2008
• Published: 03/11/2010
• Est. Priority Date: 02/01/2007
• Status: Active Grant

• Current Assignee: Locate Therapeutics Limited
• Original Assignee: Regentec Limited
• Inventors: Quirk, Robin Andrew, Ginty, Patrick, Shakesheff, Kevin Morris
• Granted Patent: US 10,195,309 B2
• Time in Patent Office: Days
• US Class Current: 523/113
• CPC Class Codes: A61L 2300/602 Type of release, e.g. controlled, sustained, slow
• CPC Class Codes: A61L 2400/06 Flowable or injectable implant compositions
• CPC Class Codes: A61L 27/26 Mixtures of macromolecular compounds
• CPC Class Codes: A61L 27/38 containing added animal cells organs or tissue containing native cells A61L27/36
• CPC Class Codes: A61L 27/50 Materials characterised by their function or physical properties , e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
• CPC Class Codes: A61L 27/502 Plasticizers
• CPC Class Codes: A61L 27/54 Biologically active materials, e.g. therapeutic substances A61L27/227 takes precedence
• CPC Class Codes: A61L 27/58 Materials at least partially resorbable by the body
• CPC Class Codes: A61L 27/60 Materials for use in artificial skin
• CPC Class Codes: C08L 67/04 Polyesters derived from hydroxycarboxylic acids, e.g. lactones C08L67/06 takes precedence
• CPC Class Codes: C08L 71/02 Polyalkylene oxides

Abstract

A composition comprising polymer particles and a carrier, wherein the polymer particles are a mixture of at least a first polymer and a second polymer, wherein the first polymer is at least partially soluble or dispersible in the carrier, and wherein the polymer particles are arranged such that they can join together to form a scaffold of polymer particles, and wherein the composition is administrable to a human or non-human animal.

Claims

1. A composition comprising polymer particles and a carrier, wherein the polymer particles are a mixture of at least a first polymer and a second polymer, wherein the first polymer is at least partially soluble or dispersible in the carrier, and wherein the polymer particles are arranged such that they can join together to form a scaffold of polymer particles, and wherein the composition is administrable to a human or non-human animal.

2. The composition of claim 1, wherein the composition is administrable to a human or non-human animal prior to the joining together of polymer particles to form a scaffold of polymer particles.

3. The composition of claim 1, wherein the polymer particles are a mixture of a first polymer together with a second polymer, wherein the mixture of the two polymers has a glass transition temperature lower than the glass transition temperature of the second type of polymer on its own.

4. The composition of claim 3, wherein the mixture of the two polymers has a glass transition temperature of 45°

C. or less.

5. The composition of claim 4, wherein the mixture of the two polymers has a glass transition temperature of 37°

C. or less and wherein the second type of polymer particle on its own has a glass transition temperature of 37°

C. or higher.

6. The composition of claim 1 wherein the first polymer is a plasticiser.

7. The composition of claim 6 wherein the plasticiser is selected from:

polyethylene glycol (PEG), poly(propylene adipate) (PPA), polyt(butylene adipate) (PBA), poly lactic acid (PLA) , polyglycolic acids (PGA), poly(D,Lvlactide-co-glycolide)(PLGA), poly propylene glycol, poly capralactone, polyethylene glycol polypropylene block co-polymers, and low molecular weight oligomers of any of the preceding polymers.

8. The composition of claim 7 wherein the plasticiser is PEG having a molecular weight of 800 or less.

9. The composition of claim 8 wherein the plasticiser is PEG having a molecular weight of 400 or less.

10. The composition of claim 1 wherein the first polymer causes chain mobilization in the second polymer, lowering the glass transition temperature and hence causing the material to soften as lower temperatures than would otherwise be possible.

11. The composition of claim 1 wherein the amount of the first polymer present in the polymer particles is from 1 to 20% by weight.

12. The composition of claim 10 wherein the amount of the first polymer present in the polymer particles is from 3 to 10% by weight.

13. The composition of claim 1 wherein the second polymer is an amorphous or semi crystalline polymer.

14. The composition of claim 13 wherein the second polymer is selected from the group comprising poly lactic acid (PLA), polyglycolic

acids, poly(D,L-lactide-co-glycolide)(PLGA), poly D,L-lactic acid (PDLLA), poly-lactide poly-glycolide copolymers and combinations thereof.

15. The composition of claim 14 wherein the first polymer is PEG and the second polymer is PLGA.

16. The composition of claim 1 wherein the carrier is an aqueous carrier.

17. The composition of claim 16 wherein the carrier is water or an aqueous solution or suspension selected from saline, plasma, bone marrow aspirate, buffers, simulated body fluids, plasma platelet concentrate and tissue culture medium.

18. The composition of claim 1 wherein the ratio of polymer to carrier is from 4:

1 to 1;

4.

19. (canceled)

20. (canceled)

21. A scaffold produced by providing a composition comprising polymer particles and a carrier, wherein the polymer particles are a mixture of at least a first polymer and a second polymer, wherein the first polymer is at least partially soluble or dispersible in the carrier, and wherein the polymer particles are arranged such that they can join together to form a scaffold of polymer particles, and wherein the composition is administrable to a human or non-human animal;

and causing the polymer particles to join together to form a solid scaffold.

22. (canceled)

23. (canceled)

24. (canceled)

25. (canceled)

26. (canceled)

27. A kit for use in producing a tissue scaffold comprising a composition comprising polymer particles and a carrier, wherein the polymer particles are a mixture of at least a first polymer and a second polymer, wherein the first polymer is at least partially soluble or dispersible in the carrier, and wherein the polymer particles are arranged such that they can join together to form a scaffold of polymer particles, and wherein the composition is administrable to a human or non-human animal and instructions to use the composition.

28. The kit of claim 27, further including a syringe for use in injecting the composition.

29. (canceled)

30. (canceled)